drugset / Trial / NCT01585792

Double Blind Comparative Study of TAK-875

NCT01585792

Phase 3 Completed 80 enrolled Takeda
Treatment

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Timeline

Start
2012-05
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasiglifam Small molecule 25 mg
Subject Fasiglifam Small molecule 50 mg
Comparator Glimepiride Small molecule

Indications

No indication recorded.